XLO - xiliotx.com Long-Term Debt

Brandmark of Xilio Therapeutics Inc (XLO)

This chart of the market valuation of Xilio Therapeutics, Inc. (XLO) debt obligations, which stands at 0.01, demonstrates business stability. The company's operations remain independent of market fluctuations, providing immunity to financial crises. The operating model relies on external contract researchers while retaining intellectual property rights. This approach complements its image as a leader in creating targeted drugs that destroy only malignant cells.

XLO - Xilio Therapeutics, Inc. Company Long-Term Liabilities over the range 07/04/2022 - 10/31/2026

Xilio Therapeutics - analytical breakdowns and key metrics (XLO)

- current quotes and average value forecast:
Stock Quotes Xilio Therapeutics Inc|XLO - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Xilio Therapeutics|XLO - Total Company Value
- book capitalization data:
Accounting Value of a Share Xilio Therapeutics|XLO - Company Net Assets|Market Value to Book Value xiliotx.com|XLO - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Equity Ratio Xilio Therapeutics, Inc.|XLO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Xilio Therapeutics Inc|XLO - Company Debts|Debt to Net Assets Ratio Xilio Therapeutics|XLO - Company Long-Term Debts|Short-Term Debt Xilio Therapeutics|Immediate Liquidity Ratio xiliotx.com
- earnings and market ratios statistics:
XLO - Net Profit
Analysis of all company metrics:Xilio Therapeutics, Inc.
Mass-produced product of Xilio Therapeutics

The stability of long-term liabilities determines the issuer's creditworthiness, while the time series of Xilio Therapeutics, Inc. (XLO) long-term debt reflects the aggregate of loans with maturities exceeding one year to assess financial leverage. A decrease in this metric confirms the resilience of Xilio Therapeutics, Inc. (XLO), which, combined with optimized logistics for the supply of chemical formulas, minimizes operational risks and ensures the continuity of clinical developments.

Who Xilio Therapeutics, Inc. competes with

ONC - Company Long-Term Liabilities|Halozyme - Company Long-Term Debts|Long-Term Debt Revolution Medicines Inc|Ascentage (AAPG) - Company Long-Term Debt|CG Oncology Therapeutics - Company Long-Term Loans and Borrowings|Company Long-Term Liabilities URGN|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Debts PSNL|Company Long-Term Liabilities Erasca Inc ERAS|Delcath - Company Long-Term Liabilities|Company Long-Term Debts Y-mAbs Corp YMAB|AURA - Company Long-Term Debt|Company Long-Term Loans and Borrowings CADL (Candel Therapeutics)|ARAY: Company Long-Term Debts|Long-Term Debt SELLAS Life Sciences Group (SLS)|Company Long-Term Liabilities ACTU|Company Long-Term Indebtedness CTOR (Citius Oncology Inc)|Company Long-Term Debts HURA|Long-Term Debt Volume protaratx.com|Company Long-Term Debt Fate Therapeutics FATE|Aadi Bioscience, Inc. - Company Long-Term Debt|TScan - Company Long-Term Debts|Long-Term Debt Volume Champions Oncology CSBR|xbiotech.com (XBIT) - Company Long-Term Debt|Long-Term Debt CEL-SCI (CVM)|Company Long-Term Liabilities OSTX|RADX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities ARTV (Artiva Biotherapeutics, Inc.)|Amount of Long-Term Liabilities ANL|Company Long-Term Debts VERU (Veru Inc.)|Company Long-Term Loans and Borrowings TPST|Enochian BioSciences - Company Long-Term Debts|Long-Term Debt Mural Oncology plc|kairospharma.com (KAPA) - Company Long-Term Debt|OnKure Therapeutics - Company Long-Term Loans and Borrowings|GDTC (CytoMed Therapeutics Ltd) - Company Long-Term Debts|Company Long-Term Debts Curis Corp|Company Long-Term Debt Apollomics, Inc. (APLM)|THAR: Long-Term Liabilities|Company Long-Term Debts ADVB (Advanced Biomed)|Genprex Inc (GNPX) - Long-Term Debt|CLDI: Company Long-Term Liabilities|SBFM - Company Long-Term Debts|XBIO (xeneticbio.com) - Company Long-Term Liabilities|SLRX: Amount of Long-Term Liabilities|PPBT (Purple Biotech Corp) - Company Long-Term Debts|AON (AONC) - Long-Term Debt Volume|Company Long-Term Debts BGNE|Company Long-Term Liabilities checkpointtx.com CKPT|Company Long-Term Debt Elevation Oncology, Inc. ELEV|Long-Term Debt Volume iCAD Inc. (ICAD)|IKNA: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NTBL (Notable Labs Corp)|VIRX: Company Long-Term Debts|MOR - Long-Term Debt Volume|Company Long-Term Debt NAYA Biosciences Inc.|Company Long-Term Indebtedness AAPGV (Ascentage Pharma Group International)